Ann: MSB Therapy Shows Benefit In First Cohort Of RA Patients, page-4

At the end of week 1, you meet FDA target

71% of MPC-treated patients who achieved ACR20 responses did so as early as week 1

At week 12 your drug exceeds it and placebo goes nowhere

At week 12, 27% of MPC-treated patients, but no placebo-treated controls, achieved ACR50 or ACR 70 responses

At this LOW dose, 20% of patients show remission

Remission at week 12, as defined by Disease Activity Score (DAS28/CRP) <2.6, was seen in 20% of MPC-treated patients but in no controls.

These are the least responsive group of patients they could find and they got a good result

GLTAH